263 related articles for article (PubMed ID: 37502435)
21. Minimal Hepatic Encephalopathy in Indians: Psychometric Hepatic Encephalopathy Score and Inhibitory Control Test for Diagnosis and Rifaximin or Lactulose for Its Reversal.
Pawar VB; Surude RG; Sonthalia N; Zanwar V; Jain S; Contractor Q; Rathi PM
J Clin Transl Hepatol; 2019 Dec; 7(4):304-312. PubMed ID: 31915599
[No Abstract] [Full Text] [Related]
22. Current approach to treatment of minimal hepatic encephalopathy in patients with liver cirrhosis.
Moran S; López-Sánchez M; Milke-García MDP; Rodríguez-Leal G
World J Gastroenterol; 2021 Jun; 27(22):3050-3063. PubMed ID: 34168407
[TBL] [Abstract][Full Text] [Related]
23. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
[TBL] [Abstract][Full Text] [Related]
24. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.
Zacharias HD; Zacharias AP; Gluud LL; Morgan MY
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012334. PubMed ID: 31204790
[TBL] [Abstract][Full Text] [Related]
25. Preventive and therapeutic effects of rifaximin on hepatic encephalopathy with differential application dosages and strategies: a network meta-analysis.
Fang G; Liu S; Liu B
BMC Gastroenterol; 2024 Mar; 24(1):94. PubMed ID: 38439005
[TBL] [Abstract][Full Text] [Related]
26. Comparison of probiotics and lactulose in the treatment of minimal hepatic encephalopathy in rats.
Jia L; Zhang MH
World J Gastroenterol; 2005 Feb; 11(6):908-11. PubMed ID: 15682492
[TBL] [Abstract][Full Text] [Related]
27. l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials.
Bai M; Yang Z; Qi X; Fan D; Han G
J Gastroenterol Hepatol; 2013 May; 28(5):783-92. PubMed ID: 23425108
[TBL] [Abstract][Full Text] [Related]
28. Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a meta-analysis.
Luo M; Li L; Lu CZ; Cao WK
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1250-7. PubMed ID: 21971378
[TBL] [Abstract][Full Text] [Related]
29. Can Lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy.
Ziada DH; Soliman HH; El Yamany SA; Hamisa MF; Hasan AM
Arab J Gastroenterol; 2013 Sep; 14(3):116-22. PubMed ID: 24206740
[TBL] [Abstract][Full Text] [Related]
30. Multistrain probiotic and lactulose in the treatment of minimal hepatic encephalopathy.
Shavakhi A; Hashemi H; Tabesh E; Derakhshan Z; Farzamnia S; Meshkinfar S; Shavakhi S; Minakari M; Gholamrezaei A
J Res Med Sci; 2014 Aug; 19(8):703-8. PubMed ID: 25422653
[TBL] [Abstract][Full Text] [Related]
31. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy.
Agrawal A; Sharma BC; Sharma P; Sarin SK
Am J Gastroenterol; 2012 Jul; 107(7):1043-50. PubMed ID: 22710579
[TBL] [Abstract][Full Text] [Related]
32. Minimal hepatic encephalopathy in cirrhosis- how long to treat?
Goyal O; Sidhu SS; Kishore H
Ann Hepatol; 2017 Jan-Feb 2017; 16(1):115-122. PubMed ID: 28051800
[TBL] [Abstract][Full Text] [Related]
33. Predictors of nonresponse to lactulose for minimal hepatic encephalopathy in patients with cirrhosis.
Sharma P; Sharma BC; Sarin SK
Liver Int; 2009 Oct; 29(9):1365-71. PubMed ID: 19555401
[TBL] [Abstract][Full Text] [Related]
34. Beneficial effects of L-ornithine L-aspartate for prevention of overt hepatic encephalopathy in patients with cirrhosis: a systematic review with meta-analysis.
Butterworth RF
Metab Brain Dis; 2020 Jan; 35(1):75-81. PubMed ID: 31338724
[TBL] [Abstract][Full Text] [Related]
35. Systematic review and meta-analysis of randomized trials on probiotics for hepatic encephalopathy.
Holte K; Krag A; Gluud LL
Hepatol Res; 2012 Oct; 42(10):1008-15. PubMed ID: 22548675
[TBL] [Abstract][Full Text] [Related]
36. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis.
Liu Q; Duan ZP; Ha DK; Bengmark S; Kurtovic J; Riordan SM
Hepatology; 2004 May; 39(5):1441-9. PubMed ID: 15122774
[TBL] [Abstract][Full Text] [Related]
37. Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy.
Sidhu SS; Goyal O; Parker RA; Kishore H; Sood A
Liver Int; 2016 Mar; 36(3):378-85. PubMed ID: 26201713
[TBL] [Abstract][Full Text] [Related]
38. Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: A multicenter, randomized controlled trial.
Wang JY; Bajaj JS; Wang JB; Shang J; Zhou XM; Guo XL; Zhu X; Meng LN; Jiang HX; Mi YQ; Xu JM; Yang JH; Wang BS; Zhang NP
J Dig Dis; 2019 Oct; 20(10):547-556. PubMed ID: 31448533
[TBL] [Abstract][Full Text] [Related]
39. L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial.
Jain A; Sharma BC; Mahajan B; Srivastava S; Kumar A; Sachdeva S; Sonika U; Dalal A
Hepatology; 2022 May; 75(5):1194-1203. PubMed ID: 34822189
[TBL] [Abstract][Full Text] [Related]
40. Probiotics in management of hepatic encephalopathy.
Sharma BC; Singh J
Metab Brain Dis; 2016 Dec; 31(6):1295-1301. PubMed ID: 27121846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
